+1.224.938.9523

HUMAN AMYLOID IMAGING CONFERENCE

January 16-18, 2019
Miami, Florida

2019 PRELIMINARY PROGRAM

The event will be held at the Miami Beach Resort.  Access to all sessions, meals, networking receptions will require a conference badge.  Please review additional Attendee FAQ.

Note: this preliminary program will continue to be edited throughout December.

HAI’s mobile app provides all the information on the program (with ability to save sessions to your conference schedule), poster presentations, FAQs, logistics, past years’ keynote videocasts, etc.   

Scan the QR code with your mobile phone or access the download through this link: https://my.yapp.us/HAICONF

 

Wednesday, January 16, 2019
10:30 amCheck-in (Grande Promenade Foyer)
11:45Welcome NotesKeith Johnson, Massachusetts General Hospital, Boston, MA, US
12:00 pmSESSION 1: Tracer propertiesCHAIRS:
Roger Gunn, Invicro, Boston, MA, US/Imperial College London, London, UK
Bradley Christian, University of Wisconsin-Madison, Madison, WI, US
12:00Head-to-head in vivo comparison of tau positron emission tomography ligands [18F]Flortaucipir (AV1451) and [18]RO948Michael Schöll, University of Gothenburg, Gothenburg, Sweden
12:15Retrospective comparison of [F-18]MK-6240, [F-18]THK5351 and [F-18]THK-5317 ((S)-THK-5117) in subjects scanned with all three PET tracersTobey Betthauser, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, US
12:30Head-to-Head Comparison of neurofibrillary tangles imaging in Alzheimer's diseasePedro Rosa-Neto, McGill University, Montreal, QC, Canada
12:45Assessment of longitudinal change of tau pathology in Alzheimer's disease using [18F]GTP1 (Genentech tau probe 1) PET imagingSandra Sanabria Bohorquez, Genentech, Inc., South San Francicso, CA, US
1:00Evaluation of 18F-PI-2620, a novel selective tau tracer for the assessment of Alzheimer's and non-Alzheimer's tauopathies
Victor Villemagne, Austin Health/The University of Melbourne, Melbourne, Australia
1:15Evidence of differential in vitro and in vivo binding of APN-1607 in progressive supranuclear palsy and Alzheimer's disease
Cristian Salinas, Biogen, Cambridge, MA, US
1:30Discussion Session 1
2:00POSTER SESSION 1 and Coffee Break
3:30SESSION 2: MethodsCHAIRS:
Robert Koeppe, University of Michigan Medical School, Ann Arbor, MI, US
Mark Lubberink, Uppsala University, Uppsala, Sweden
3:30Variability of uptake in potential reference regions for longitudinal flortaucipir-PET analysisJungho Cha, University of California, San Francisco, San Francisco, CA, US
3:45Test-retest repeatability of [18F]Flortaucipir PET in Alzheimer's disease and controlsTessa Timmers, Amsterdam UMC, Amsterdam, The Netherlands
4:00AmyloidIQ demonstrates increased power in longitudinal Amyloid PET studies
Alexander Whittington, Invicro, Boston, MA, US/Imperial College London, London, UK
4:15Regionalized spatial association between PiB and FTP PET assessed via variographyTobias Estime, Massachusetts General Hospital, Boston, MA, US
4:30Evaluation of the Centiloid scale for use in multi-amyloid PET tracer, multi-center trials
Jacob Hesterman, Invicro, Boston, MA, US
4:45A comparison of partial volume correction techniques for measuring change in Serial AV-1451 Tau PET SUVR
Christopher Schwarz, Mayo Clinic, Rochester, MN, US
5:00Detecting the earlier stages of amyloid deposition
Tengfei Guo, University of California, Berkeley, CA, US
5:15Discussion Session 2
5:45Keynote LectureRichard Carson, Yale University, New Haven, CT, US
6:15Keynote Discussion
6:30-8:30Welcome Reception
Thursday, January 17, 2019
7:30amCheck-in (Grande Promenade Foyer) and Breakfast (Starlight Ballrooom - 18th Floor)
8:30SESSION 3: Neuropathological validation of amyloid and tau tracersCHAIRS:
Laetitia Lemoine, Karolinska Institute, Stockholm, Sweden
Rik Vandenberghe, KU Leuven, Leuven, Belgium
8:30Neuropathologic correlates of [11C]PiB PET and [11C]altropane dopamine transporter PET in the Lewy body diseasesStephen Gomperts, Massachusetts General Hospital, Boston, MA, US
8:45Postmortem analyses of PiB and Flutemetamol integrated density measures in diffuse and neuritic plaques in Alzheimer's disease
Milos Ikonomovic, University of Pittsburgh, Pittsburgh, PA, US
9:00In vitro characterisation of 3H-MK6240 in human autopsy brain tissue in comparison to the first generation tau PET tracersMona-Lisa Malarte, Karolinska Institute, Stockholm, Sweden
9:15Postmortem binding study of 18F-AV1451 in semantic variant primary progressive aphasiaRik Vandenberghe, University Hospitals Leuven/KU Leuven, Leuven, Belgium
9:30Neuropathologic maturity of neurofibrillary tangles: implications for tau PET imagingMelissa Murray, Mayo Clinic Jacksonville, Jacksonville, FL, US
9:45Discussion Session 3
10:15POSTER SESSION 2A and Coffee Break
11:00SESSION 4: In vivo-postmortem correlates of flortaucipir PETCHAIRS:
Teresa Gomez-Isla, Massachusetts General Hospital, Boston, MA, US
David Wolk, University of Pennsylvania, Philadelphia, PA, US
11:00Pathologic correlations of in vivo [18F]-AV-1451 imaging in autopsy-confirmed Alzheimer's disease, Frontotemporal lobar degeneration with TDP-43 inclusions and control casesCinthya Aguero, MassGeneral Institute for Neurodegenerative Disease, Charlestown, MA, US
11:15[18F]Flortaucipir PET and pathology correlations in Alzheimer's disease, non-Alzheimer's tauopathies, and other neurodegenerative diseasesDavid Soleimani-Meigooni, University of California, San Francisco, San Francisco, CA, US
11:30Tau PET imaging correlates with neuropathologyVal Lowe, Mayo Clinic, Rochester, MN, US
11:45Relationships between Flortaucipir PET signal and tau neurofibrillary tangle pathology at autopsyMark Mintun, Avid Radiopharmaceuticals, Philadelphia, PA, US
12:00Discussion Session 4
12:30Keynote Lecture
(This lecture will be recorded)
Michel Goedert, MRC Laboratory of Molecular Biology, Cambridge, UK
1:00Keynote Discussion
1:15Lunch
2:45SESSION 5: Modeling amyloid & tau relationships and spreadCHAIRS:
Elizabeth Mormino, ‎Stanford University, Palo Alto, CA, US
Michel Grothe, German Center for Neurodegenerative Diseases, Rostock, Germany
2:45Data-driven characterization of cross-sectional and longitudinal molecular imaging in aging and Alzheimer's diseaseHugo Botha, Mayo Clinic, Rochester, MN, US
3:00The cortical site of origin and initial spread of medial temporal tauopathy assessed with positron emission tomographyJustin Sanchez, Massachusetts General Hospital, Boston, MA, US
3:15Amyloid and tau pathology are related to functional signal homogeneity and isolation of the hippocampus in cognitively healthy older adultsTheresa Harrison, University of California Berkeley, Berkeley, CA, US
3:30Cross-method identification of earliest regions to display amyloid burdenIsadora Lopes Alves, VU University Medical Center, Amsterdam, The Netherlands
3:45Tau organization precedes Aβ deposition across the brain cortexTharick Pascoal, McGill University, Montreal, QC, Canada
4:00Increased task activation and amyloid independently explain advanced tau pathology in older adultsAnne Maass, German Center for Neurodegenerative Diseases, Magdeburg, Germany
4:15Discussion Session 5
4:45POSTER SESSION 2B and Coffee Break
5:30 - 7:30Networking Reception
Friday, January 18, 2018
7:30amCheck-in (Grande Promenade Foyer) and Breakfast (Starlight Ballrooom - 18th Floor)
8:30SESSION 6: PET and fluid biomarkersCHAIRS:
Oskar Hansson, Lund University, Lund, Sweden
Susan Landau, University of California, Berkeley, Berkeley, CA, US
8:30Longitudinal investigation of concordant vs. discordant amyloid CSF/PET biomarkersArianna Sala, Karolinska Institute, Stockholm, Sweden
8:45CSF and PET tau measures in different stages of Alzheimer's disease
Niklas Mattsson, Lund University, Lund, Sweden
9:00Predicting brain amyloidosis using peripheral blood-based gene expression and early stage neurodegeneration biomarkersApoorva Bharthur Sanjay, Indiana University School of Medicine, Indianapolis, IN, US
9:15Friend or foe? Regional dependent roles of neuroinflammation in Alzheimer's disease pathophysiologyMin Su Kang, McGill Centre for Studying in Aging, Verdun, QC, Canada
9:30Discussion Session 6
10:00POSTER SESSION 3A and Coffee Break
10:45SESSION 7: Multi-modality: cognitively normalCHAIRS:
William Jagust, University of California, Berkeley, Berkeley, CA, US
Tobey Betthauser, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, US
10:45Protective effect of physical activity on prospective cognitive decline and longitudinal neurodegeneration in clinically normal older adults with elevated β-amyloid burdenJennifer Rabin, Massachusetts General Hospital, Boston, MA, US
11:00MRI measures of neurodegeneration and vascular injury, but not smyloid status predict cognitive decline in normal individuals followed for more than 9 YearsCharles DeCarli, University of California at Davis, Sacramento, CA, US
11:15Fluorodeoxyglucose and Flortaucipir PET independently predict subsequent cognitive decline in clinically normal adults with elevated amyloidBernard Hanseeuw, Massachusetts General Hospital, Boston, MA, US
11:30MK-6240 and PIB PET are associated with retrospective cognitive trajectories in late-middle aged persons clinically unimpaired at baselineSterling Johnson, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, US
11:45Individual variations in sleep architecture are associated with tau PET, cognition, and functional network architecture: preliminary findings from the Harvard Aging Brain StudyJasmeer Chhatwal, Massachusetts General Hospital, Boston, MA, US
12:00Discussion Session 7
12:30Keynote Lecture:
Tau strains and spreading in pure tauopathies and Alzheimer’s disease

(This lecture will be recorded)
John Trojanowski, University of Pennsylvania, Philadelphia, PA, US
1:00Keynote Discussion
1:15Lunch
2:30SESSION 8: Multi-modality: patient populationsCHAIRS:
Ann Cohen, University of Pittsburgh, Pittsburgh, PA, US
Keith Johnson, Massachusetts General Hospital, Boston, MA, US
2:30Tau imaging with [18F]Flortaucipir predicts the severity and the topography of subsequent cortical atrophy in patients with Alzheimer's diseaseRenaud La Joie, University of California, San Francisco, San Francisco, CA, USA
2:45Epidemic spreading of tau through human functional brain connectionsJacob Vogel, Montreal Neurological Institute, McGill University, Montreal, QC, Canada
3:00Spatial extent and topographical relationships between pathology accumulation and neurodegeneration in Alzheimer's diseaseLeonardo Iaccarino, University of California San Francisco, San Francisco, CA, USA, San Francisco, CA, US
3:15Functional connectivity associated with tau levels in aging, Alzheimer's, and small-vessel diseaseNicolai Franzmeier, Ludwig-Maximilians-Universität LMU, Munich, Germany
3:30Associations between longitudinal Aβ and cross-sectional tau in adults with Down syndrome
Dana Tudorascu, University of Pittsburgh, Pittsburgh, PA, US
3:45Discussion Session 8
4:15POSTER SESSION 3B and Coffee Break
5:00Awards Ceremony
5:05SESSION 9: Clinical applicationsCHAIRS:
Pedro Rosa-Neto, McGill University, Montreal, QC, Canada
Gil Rabinovici, University of California, San Francisco, CA, US
5:05Tau PET imaging with 18F-PI2620 in aging and neurodegenerative diseasesElizabeth Mormino, Stanford University, Palo Alto, CA, US
5:20In vivo distribution pattern of 18F-PM-PBB3 (18F-APN-1607) and its relationship with clinical features in diverse 4-repeat tauopathiesHitoshi Shimada, National Institute of Radiological Sciences/National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
5:35
Tau imaging with 18F-MK6240 in Alzheimer's disease and in past traumatic brain injuryChristopher Rowe, Austin Health/The University of Melbourne, Melbourne, Australia
5:50[18F]-AV-1451 binding profile in early and late-onset Alzheimer's disease and suspected non-Alzheimer pathophysiologyEddie Stage, Indiana University School of Medicine, Indianapolis, IN, US
6:05Towards a topographic imaging biomarker of TDP-43 pathology in amnestic dementia: patient stratification based on FDG-PET patterns in autopsy-confirmed casesMichel Grothe, German Center for Neurodegenerative Diseases, Rostock, Germany
6:20Discussion Session 9

The 17th Mild Cognitive Impairment Symposium and Special Topic Workshop (CME/CE accredited) will follow immediately on January 19-20, 2019 at the same venue. 

MCI website

2019 KEYNOTE LECTURES


RICHARD CARSON, PhD

Dr. Carson received his doctorate degree from UCLA in 1983 in Biomathematics. From that time on, he has focused his research on the development and application of mathematical techniques for the study of human beings and non-human primates with Positron Emission Tomography (PET), a noninvasive imaging technology that uses radiopharmaceuticals to trace in vivo physiology and pharmacology. From 1983 until 2005, Dr. Carson was an integral part of the PET program at the National Institutes of Health, rising to the rank of Senior Scientist. In 2005, Dr. Carson joined the faculty of Yale University as Professor of Biomedical Engineering and Diagnostic Radiology. He is Director of the Yale PET Center, a state-of-the-art facility focused on quantitative PET techniques using novel radiopharmaceuticals. Dr. Carson is also Director of Graduate Studies in Biomedical Engineering.

Dr. Carson’s research interests are concentrated in the following areas: 1) New algorithms for image reconstruction with PET, 2) Development of mathematical models for novel radiopharmaceuticals to produce images of physiological parameters, 3) Use of receptor-binding ligands to measure drug occupancy and dynamic changes in neurotransmitters by analysis of PET tracer signals, and 4) applications of PET tracers in clinical populations and preclinical models of disease. Dr. Carson has published over 275 papers in peer-reviewed journals, given over 125 invited lectures and is a member of the editorial board of two of the leading journals in the field of brain PET, the Journal of Nuclear Medicine, and the Journal of Cerebral Blood Flow and Metabolism.

Dr. Carson was awarded the Kuhl-Lassen award from the Brain Imaging Council of the Society of Nuclear Medicine in 2007. He became a member of the College of Fellows of the American Institute for Medical and Biological Engineering in 2008 and was awarded the Sheffield Distinguished Teaching Award from the Yale School of Engineering. In 2009, he was named the winner of the Ed Hoffman Memorial Award from the Computer and Instrumentation Council of the Society of Nuclear Medicine. In 2010, Dr. Carson was named as a member of the Connecticut Academy of Science and Engineering. In 2016, Dr. Carson was given the Distinguished Investigator Award from the Academy of Radiology Research. In 2017, Dr. Carson received the Edward J. Hoffman Medical Imaging Scientist Award from the IEEE. In 2018, Dr. Carson gave the Henry N. Wagner Jr. Lectureship at the Society of Nuclear Medicine and Molecular Imaging annual meeting in Philadelphia.

MICHEL GOEDERT, MD, PhD

Dr. Michel Goedert elucidated some of the events leading to the ordered assembly of tau protein into abnormal filaments. Tau filaments with distinct morphologies and/or isoform compositions underlie a large number of human neurodegenerative diseases, including Alzheimer’s disease, chronic traumatic encephalopathy, tangle-only dementia, Pick’s disease, progressive supranuclear palsy, corticobasal degeneration and argyrophilic grain disease. Earlier work by Michel Goedert and colleagues on familial forms of frontotemporal dementia helped to establish the now widely accepted view that dysfunction of tau protein is sufficient to cause neurodegeneration and dementia. Michel Goedert and colleagues also broke new ground with their discovery that the abnormal filaments of Lewy bodies and Lewy neurites that are characteristic of Parkinson’s disease and dementia with Lewy bodies are made of alpha-synuclein. The same is true of the filamentous inclusions of multiple system atrophy. His work helped to establish the concept that the prion-like propagation of aggregate seeds may underlie tauopathies and synucleinopathies. More recently, work done in collaboration with Sjors Scheres used electron cryo-microscopy and immunogold negative-stain electron microscopy to determine the first high-resolution structures of disease filaments from human brain, identifying distinct conformers of assembled tau in Alzheimer’s and Pick’s diseases. These structural insights will inform understanding of how diseases begin and how they can be better diagnosed and treated.

Michel Goedert received a number of awards for his work on neurodegenerative diseases, including the Metropolitan Life Foundation Award for Medical Research in 1996 (with Yasuo Ihara, Virginia Lee, Brenda Milner and John Trojanowski), the Potamkin Prize for Research in Pick’s, Alzheimer’s, and Related Diseases in 1998 (with Virginia Lee and John Trojanowski) and the European Grand Prix for Research from the French Foundation for Research on Alzheimer’s disease in 2014. He was awarded the 2018 Brain Prize (with Bart de Strooper, Christian Haass and John Hardy) by the Danish Lundbeck Foundation “for groundbreaking research on the genetic and molecular basis of Alzheimer’s disease, with far-reaching implications for the development of new therapeutic interventions, as well as for the understanding of other neurodegenerative diseases of the brain.”

Michel Goedert, a native of Luxembourg, received an MD from the University of Basel (Switzerland) and a PhD from the University of Cambridge (United Kingdom). He has worked at the Medical Research Council Laboratory of Molecular Biology in Cambridge as a Programme Leader since 1984 and was Head (joint or sole) of its Neurobiology Division from 2003 to 2016. Since 2014, he has also been an Honorary Professor in the Department of Clinical Neurosciences of Cambridge University. Michel Goedert is a Fellow of the Royal Society, a Fellow of the UK Academy of Medical Sciences and a member of EMBO.

JOHN TROJANOWSKI, MD, PhD

Dr. John Trojanowski obtained his MD/PhD in 1976 from Tufts University in Boston. After a medicine internship at Mt. Auburn Hospital and Harvard Medical School, he began pathology/neuropathology training at Massachusetts General Hospital and Harvard Medical School (1977-1979), and completed training at the University of Pennsylvania School of Medicine in 1980 where he was appointed assistant professor of Pathology and Laboratory Medicine and rose to tenured full professor in 1990.

Dr. Trojanowski holds major leadership positions at the University of Pennsylvania including: Director of a National Institute of Aging (NIA) Alzheimer’s Disease Center (1991-present), Director (2002-present) of the Institute on Aging, Co-Director (1992-present) of the Center for Neurodegenerative Disease Research, named the first William Maul Measey -Truman G. Schnabel, Jr., M.D., Professor of Geriatric Medicine and Gerontology in 2003 and Co-director of the Marian S. Ware Alzheimer Drug Discovery Program.

For over 15 years, Dr. Trojanowski has conducted research on AD, PD, motor neuron disease, dementia with Lewy bodies , frontotemporal dementias and related disorders. Most of his 500+ publications focus on the pathobiology of neurodegenerative disorders, especially the role of abnormal filamentous protein aggregates in these diseases. Dr. Trojanowski received awards for his research including: a MERIT Award (1986-1994) from the National Institutes of Health (NIH), the Metropolitan Life Foundation Promising Investigator Award For Alzheimer’s Disease Research (1991), membership in the American Society of Clinical Investigation (1991), an Established Investigator Award from the National Alliance for Research on Schizophrenia and Depression (1994), the Metropolitan Life Foundation Award For Alzheimer’s Disease Research (1996), the Potamkin Prize For Research In Pick’s, Alzheimer’s And Related Diseases (1998), the first Pioneer Award from the Alzheimer’s Association (1998), ISI Highly Cited Researcher 2000 (most highly cited neuroscientists for 1981-1999), the Stanley Cohen Biomedical Research Award of the University of Pennsylvania (2000), membership in the Association of American Physicians (2000), the 2004 Irving Wright Award of Distinction of the American Federation for Aging Research, and the 2005 Rous-Whipple Award of the American Society for Investigative Pathology. He was elected President of the American Association of Neuropathologists (1997-1998), and is on the editorial board of several neuroscience and pathology journals.

Dr. Trojanowski was elected to the Institute of Medicine (2002) and he has served and continues to serve on local and national aging research committees including the NIA Neuroscience, Behavior and Sociology of Aging Study Section (1987-1991), the National Advisory Council on Aging (NACA) of the NIA (1994-1998), the NACA Working Group Chair (1996-1998), the Medical and Scientific Advisory Board of the National Alzheimer’s Association (1994-1997) as well as of the Southeastern Pennsylvania Chapter of the Alzheimer’s Association (1992- present), the NIA Board of Scientific Counselors (1998-present), the Scientific Advisory Boards of the Paul Beeson Physician Faculty Scholars In Aging Award (1998-present), the Alliance for Aging Research (2002-present) and the Association of Frontotemporal Dementia (2003-present), the Program Committee of the World Alzheimer Congress 2000 (1998-2000), Chair of the “Biology of Synuclein and Cortical Lewy Bodies Associated with Dementia in AD, LBD, and PD” (July, 2001) and “Genetics of Alzheimer’s Disease (March, 2002) workshops organized by NIA and the National Institute on Neurological Diseases and Stroke in Bethesda, Maryland, and the Organizing Committee of the 6th (Seville, Spain, 2003) and 7th (Sorrento, Italy, 2005) International Conferences On Progress In Alzheimer’s And Parkinson’s Disease (2001-2005).